Conoidin A (intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury) blocks the effect of Luteolin (HY-N0162) on the ST-segment elevation. Furthermore, an increase in the infarct size presented of the MI/R group can be reduced by Luteolin. But pre-treatment with conoidin A abolishs the effect of Luteolin. Pre-treatment with conoidin A also prevents Luteolin-reduced activities of CK-MB, AST and LDH in vivo[3].
| Animal Model: | Rat myocardial I/R model[3] |
| Dosage: | 5mg/kg |
| Administration: | Intraperitoneal injection; 5mg/kg; for three successive days before MI/R injury |
| Result: | Significantly reversed the antioxidative effect of Luteolin.
Impaired the protective effects of luteolin. |
